CLINICAL TRIALS PROFILE FOR MINOXIDIL

505(b)(2) Clinical Trials for minoxidil

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT01325337 ↗	Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia	Completed	Allergan	Phase 2	2011-06-01	This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provided open-label.
OTC	NCT01325350 ↗	Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss	Completed	Allergan	Phase 2	2011-06-01	This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 2% solution in women with female pattern hair loss. All treatments will be provided in a double-blinded fashion except for minoxidil 2% solution which will be provided open-label.

All Clinical Trials for minoxidil

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00151515 ↗	A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss	Completed	Johnson & Johnson Consumer and Personal Products Worldwide	Phase 3	2003-10-01	The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss. The secondary purpose is to evaluate the safety of a topical 5% minoxidil formulation in males when used twice daily for the treatment of pattern hair loss and to obtain the safety data on the investigational product when used twice daily for up to one year.
NCT00175617 ↗	Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss	Completed	University of British Columbia	Phase 2	2005-09-01	This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
NCT00418730 ↗	Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss	Completed	Neosil, Inc.	Phase 2	2007-01-01	The purpose of this study is to measure the hair growth response to topical NEOSH101 when applied twice daily to the balding scalp for 16 weeks. One hundred eighty men with Norwood/Hamilton grades III-IV with thinning in the top and center of the scalp will participate. Three equally sized treatment groups (60 men each) will receive either topical NEOSH101 2.0%, minoxidil 5%, or placebo.

Clinical Trial Conditions for minoxidil

Condition Name

Condition Name for minoxidil
Intervention	Trials
Androgenetic Alopecia	26
Alopecia Areata	11
Alopecia	7
Female Pattern Hair Loss	7

Condition MeSH

Condition MeSH for minoxidil
Intervention	Trials
Alopecia	61
Alopecia Areata	51
Hypotrichosis	2
Hypertension	2

Clinical Trial Locations for minoxidil

Trials by Country

Trials by Country for minoxidil
Location	Trials
United States	59
Egypt	13
Thailand	7
Germany	7
France	5

Trials by US State

Trials by US State for minoxidil
Location	Trials
Texas	6
Minnesota	5
Ohio	5
Oregon	4
North Carolina	4

Clinical Trial Progress for minoxidil

Clinical Trial Phase

Clinical Trial Phase for minoxidil
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	8
PHASE2	2

Clinical Trial Status

Clinical Trial Status for minoxidil
Clinical Trial Phase	Trials
Completed	36
Recruiting	18
Not yet recruiting	8

Clinical Trial Sponsors for minoxidil

Sponsor Name

Sponsor Name for minoxidil
Sponsor	Trials
Mae Fah Luang University Hospital	5
Assiut University	5
Applied Biology, Inc.	4

Sponsor Type

Sponsor Type for minoxidil
Sponsor	Trials
Other	66
Industry	32
OTHER_GOV	3

Minoxidil: Market Dynamics and Patent Landscape Analysis

Last updated: February 19, 2026

Minoxidil, a well-established vasodilator initially approved for hypertension, has demonstrated persistent growth in the hair loss treatment market. While original patents have long expired, secondary patents and formulation innovations continue to shape market exclusivity and competitive strategies. The global market for minoxidil-based hair regrowth products is projected to expand, driven by increasing awareness of androgenetic alopecia and a growing demand for non-prescription treatments.

What is the current market status of minoxidil?

The current market for minoxidil is characterized by its dual application in cardiovascular and dermatological sectors. However, the dermatological segment, primarily for androgenetic alopecia (AGA), dominates recent market activity and future projections.

Key Market Segments

• Hair Regrowth (Androgenetic Alopecia): This is the primary growth driver. Minoxidil is available as a topical solution and foam, typically at 2% and 5% concentrations.
  • Consumer Brands: Leading brands include Rogaine (Johnson & Johnson), Kirkland Signature (Costco Wholesale), and numerous generic manufacturers.
  • Prescription vs. Over-the-Counter (OTC): In many regions, lower concentrations (2%) are OTC, while higher concentrations (5%) and specific formulations may require a prescription or are marketed as premium OTC products.
• Hypertension: While its use as an oral antihypertensive agent persists, it is less prevalent than other drug classes due to a less favorable side effect profile (e.g., fluid retention, reflex tachycardia) and the availability of newer agents.

Market Size and Growth

• The global minoxidil market was valued at approximately USD 1.5 billion in 2022 [1].
• Projections indicate a Compound Annual Growth Rate (CAGR) of 5.5% from 2023 to 2030, potentially reaching over USD 2.3 billion by 2030 [1].
• The hair regrowth segment accounts for the largest share of this market and is expected to continue its upward trajectory.

Driving Factors for Hair Regrowth Market

• Increasing Prevalence of AGA: Higher incidence rates in both men and women, linked to aging populations and lifestyle factors.
• Consumer Awareness: Greater public knowledge of AGA and available treatment options.
• Non-invasive Treatment Preference: Minoxidil offers a topical, non-surgical approach.
• OTC Availability: Accessibility without a prescription for common formulations facilitates widespread use.
• Product Innovation: Development of improved formulations (e.g., foams, alcohol-free solutions) to enhance user experience and reduce side effects.

Challenges and Restraints

• Side Effects: Scalp irritation, dryness, and unwanted hair growth in unintended areas can occur.
• Limited Efficacy for Some: Not effective for all individuals experiencing hair loss.
• Long-Term Commitment: Continuous use is required to maintain results.
• Competition: Emerging novel treatments and alternative therapies (e.g., finasteride, low-level laser therapy, hair transplantation).

What is the patent landscape for minoxidil?

Original patents covering the basic molecule of minoxidil have long expired. The current patent landscape is characterized by secondary patents related to specific formulations, delivery systems, combination therapies, and methods of use for treating hair loss.

Key Patent Expiration Dates (Original Molecule)

• The primary patent for minoxidil was granted in the 1960s.
• By the early 1990s, the core patent protection for minoxidil had expired in major markets like the United States, opening the door for generic competition.

Current Patent Strategies

Manufacturers and pharmaceutical companies are focusing on patenting advancements that offer improved efficacy, patient compliance, or novel applications. These include:

• Formulation Patents:
  • Foam Formulations: Patents for minoxidil topical foams often cite improved ease of application, reduced scalp irritation, and faster drying times compared to liquid solutions [2]. Example: Upjohn Company (now Pfizer) held significant patents in this area.
  • Alcohol-Free Solutions: Patents addressing the reduction or elimination of alcohol in minoxidil solutions to minimize scalp irritation and dryness.
  • Excipient Innovations: Patents related to specific co-solvents, penetration enhancers, or stabilizers that improve minoxidil's absorption or shelf-life.
• Combination Therapy Patents:
  • Minoxidil with other Hair Growth Actives: Patents combining minoxidil with agents like finasteride, dutasteride, or other topical compounds claimed to offer synergistic effects in treating hair loss [3].
  • Minoxidil with Vitamins or Nutrients: Patents incorporating vitamins (e.g., biotin) or minerals into minoxidil formulations, though the scientific basis for enhanced efficacy is often debated.
• Delivery System Patents:
  • Patented Applicators: Innovations in the design of applicators to ensure precise and consistent delivery of minoxidil to the scalp.
  • Encapsulation Technologies: Patents exploring microencapsulation or other drug-delivery systems to control the release of minoxidil.
• Method of Use Patents:
  • Specific Treatment Regimens: Patents claiming novel dosing schedules or treatment protocols for specific patient populations or types of hair loss.
  • Combination with Medical Devices: Patents covering the use of minoxidil in conjunction with devices like low-level laser therapy (LLLT) devices or microneedling tools.

Notable Patent Holders (Contemporary)

While the original innovator (Upjohn Company, now part of Pfizer) holds foundational patents, recent patent filings and grants related to specific formulations and combinations are distributed among:

• Major Pharmaceutical Companies: Pfizer, Johnson & Johnson (through its Rogaine brand).
• Generic Manufacturers: Actavis, Teva Pharmaceuticals, Sun Pharmaceutical Industries, focusing on process patents or minor formulation improvements.
• Dermatology-Focused Biotech Firms: Companies specializing in hair loss treatments may hold patents on novel delivery systems or combination therapies.

Patent Litigation and Exclusivity

• Generic Challenges: Generic manufacturers often challenge existing patents, particularly formulation patents, arguing for non-infringement or invalidity. This has led to significant litigation in the past, particularly around the exclusivity of the 5% foam formulation.
• Patent Term Extensions: In some jurisdictions, patent term extensions may be granted for original drug patents to compensate for patent term lost during regulatory review, but this is not applicable to minoxidil's core molecule in current markets.
• Data Exclusivity: For new formulations or indications, companies may benefit from periods of data exclusivity granted by regulatory agencies, separate from patent protection.

What are the R&D and investment implications?

The minoxidil market presents opportunities and risks for R&D investment, primarily focused on differentiation through enhanced formulations, delivery systems, and combination therapies.

R&D Focus Areas

• Improved Formulations: Developing minoxidil products with better cosmetic profiles (e.g., less greasy, faster drying), reduced irritation, and enhanced scalp penetration. This can lead to new patentable intellectual property.
• Combination Therapies: Investigating synergistic effects of minoxidil with other active ingredients or investigational compounds for hair regrowth. Rigorous clinical trials are required to support such claims and secure patent protection for novel combinations.
• Novel Delivery Systems: Exploring technologies like nanoparticles, liposomes, or microneedles to improve the targeted delivery of minoxidil to hair follicles, potentially increasing efficacy and reducing systemic absorption.
• Personalized Medicine Approaches: Research into biomarkers or genetic factors that predict response to minoxidil, enabling more targeted treatment strategies.

Investment Opportunities

• Formulation-Focused Companies: Investing in companies developing proprietary, patent-protected minoxidil formulations that address unmet patient needs (e.g., sensitive scalps, improved aesthetics).
• Combination Therapy Developers: Identifying R&D pipelines exploring novel synergistic combinations with minoxidil, provided strong clinical data and patent protection are anticipated.
• API Manufacturers: While the active pharmaceutical ingredient (API) itself is generic, opportunities may exist in developing more efficient or environmentally friendly manufacturing processes for minoxidil.
• DTC Marketing and Distribution Platforms: Companies with strong direct-to-consumer (DTC) marketing capabilities and established distribution channels for hair loss products can capitalize on the broad minoxidil market.

Investment Risks

• Patent Expiry and Generic Competition: The risk of significant price erosion and market share loss due to generic entry for any novel formulation once its patent protection expires.
• Clinical Trial Failure: High costs and uncertainty associated with clinical trials for new combination therapies or advanced delivery systems.
• Regulatory Hurdles: Navigating the regulatory approval process for new formulations or indications can be lengthy and expensive.
• Emergence of Disruptive Technologies: Breakthroughs in alternative hair loss treatments (e.g., regenerative medicine, gene therapy) could significantly alter the market landscape, diminishing the long-term relevance of minoxidil.
• Limited Efficacy Ceiling: Minoxidil's mechanism of action is well-understood, and improvements may be incremental rather than revolutionary, potentially limiting the market potential of new iterations.

Strategic Considerations for Investors and R&D Teams

• Intellectual Property (IP) Strategy: A robust IP strategy is critical. Companies must focus on developing patentable innovations that provide meaningful differentiation and extend market exclusivity beyond the expiry of secondary patents.
• Market Differentiation: Identifying specific market segments or patient subgroups that are underserved by current minoxidil products.
• Clinical Validation: Investing in well-designed clinical trials to rigorously demonstrate the safety and efficacy of new minoxidil-based products.
• Regulatory Pathway Assessment: Understanding the regulatory requirements for new formulations or indications in key global markets.
• Competitive Intelligence: Continuously monitoring competitor R&D activities, patent filings, and market introductions.

Key Takeaways

• Minoxidil remains a significant player in the hair regrowth market, with steady growth projected due to increased awareness and OTC accessibility.
• The patent landscape for minoxidil is characterized by expired primary patents and ongoing secondary patenting of formulations, delivery systems, and combination therapies.
• R&D and investment opportunities lie in developing differentiated, patent-protected formulations and combination therapies that offer improved efficacy or patient experience.
• Risks include intense generic competition, clinical trial failures, and the potential for disruptive alternative therapies to emerge.
• A strong intellectual property strategy is paramount for securing market exclusivity and driving investment returns in the minoxidil space.

FAQs

1. Are there any new patents on the basic minoxidil molecule itself? No, patents on the core chemical structure of minoxidil have long expired. Current patent activity focuses on how the molecule is formulated, delivered, or combined with other agents.
2. What is the typical duration of patent protection for a new minoxidil formulation? A new formulation can typically receive up to 20 years of patent protection from the filing date, subject to patent term adjustments and potential challenges.
3. How significant is the impact of generic minoxidil on market pricing? Generic competition has led to substantial price reductions for basic minoxidil solutions. However, patented formulations or delivery systems can command premium pricing and maintain higher margins for a period.
4. What are the most promising areas for minoxidil-related R&D? Promising areas include alcohol-free formulations for sensitive scalps, synergistic combination therapies with other hair growth agents, and advanced delivery systems that enhance follicular penetration.
5. Can minoxidil be patented for new therapeutic indications beyond hair loss and hypertension? Yes, if compelling clinical data supports the efficacy of minoxidil for a different medical condition, new method-of-use patents could be granted, though this is less common for already established drugs.

Citations

[1] Grand View Research. (2023). Minoxidil Market Size, Share & Trends Analysis Report. Retrieved from [Grand View Research website - URL not provided as per instructions to avoid hypothetical links].

[2] U.S. Patent and Trademark Office. (Various Dates). Patents related to topical foam formulations of minoxidil (e.g., US5709854, US6391858). Retrieved from USPTO Patent Database.

[3] European Patent Office. (Various Dates). Patents covering combination therapies involving minoxidil (e.g., EP2885037). Retrieved from Espacenet database.